Literature DB >> 24619495

HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma.

Won Sohn1, Yong-Han Paik, Jong Man Kim, Choon Hyuk Kwon, Jae Won Joh, Ju Yeon Cho, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo.   

Abstract

BACKGROUND: Recent studies have shown that high hepatitis B virus (HBV) load is associated with increased risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). The aim of our study was to investigate the predictive role of HBV DNA and hepatitis B surface antigen (HBsAg) levels in early and late recurrence of HCC after curative resection in patients with HBV-related HCC.
METHODS: From January 2008 to December 2010, a total of 248 patients underwent curative resection for HBV-related early-stage HCC (solitary tumor; < 5 cm in diameter or multinodular tumor; number of tumors ≤ 3 and diameter < 3 cm). We analyzed the predictive factors including HBV DNA and HBsAg levels for early recurrence (within 2 years) and late recurrence (after 2 years) of HCC after curative resection.
RESULTS: The median follow-up duration was 33.3 months. Cumulative recurrence rates after resection at 1, 3, and 5 years were 16.6, 34.0, and 46.7 %, respectively. The multivariate analysis showed that risk factors for early recurrence were the presence of microvascular invasion (hazard ratio [HR] 3.86; p < 0.001), preoperative HBV DNA levels ≥ 20,000 IU/mL (HR 2.77; p < 0.001), and des-γ-carboxy prothrombin level ≥ 40 mAU/mL (HR 1.76; p = 0.045). Although, the risk factors for late recurrence by multivariate analysis were preoperative HBsAg levels ≥ 4,000 IU/mL (HR 2.80; p = 0.023) and age at resection ≥ 50 years (HR 3.22; p = 0.032).
CONCLUSION: The HBV DNA levels were associated with early recurrence, whereas HBsAg levels were associated with late recurrence after curative resection in HBV-related HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24619495     DOI: 10.1245/s10434-014-3621-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  40 in total

1.  MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma.

Authors:  Young Wha Koh; Yang-Soon Park; Hyo Jeong Kang; Ju Hyun Shim; Eunsil Yu
Journal:  Tumour Biol       Date:  2015-02-10

2.  Adjuvant antiviral therapy for the prevention of hepatocellular carcinoma recurrence after liver resection: indicated for all patients with chronic hepatitis B?

Authors:  Clifford Akateh; Timothy M Pawlik; Jordan M Cloyd
Journal:  Ann Transl Med       Date:  2018-10

3.  Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load.

Authors:  Hua-Bang Zhou; Qiao-Mei Li; Zheng-Rong Zhong; Jing-Yi Hu; Xiao-Lan Jiang; Hao Wang; Hui Wang; Bing Yang; He-Ping Hu
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

4.  Risk Factors for Early Recurrence of Single Lesion Hepatocellular Carcinoma After Curative Resection.

Authors:  Mitsugi Shimoda; Kazuma Tago; Takayuki Shiraki; Shozo Mori; Masato Kato; Taku Aoki; Keiichi Kubota
Journal:  World J Surg       Date:  2016-10       Impact factor: 3.352

5.  Robotic versus laparoscopic left lateral sectionectomy of liver.

Authors:  Jae Keun Kim; Joon Seong Park; Dai Hoon Han; Gi Hong Choi; Kyung Sik Kim; Jin Sub Choi; Dong Sup Yoon
Journal:  Surg Endosc       Date:  2016-02-22       Impact factor: 4.584

Review 6.  Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation.

Authors:  Li-Ying Wang; Shu-Sen Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2018-07       Impact factor: 3.066

7.  Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma.

Authors:  Zheng Li; Zhengqing Lei; Yong Xia; Jun Li; Kui Wang; Han Zhang; Xuying Wan; Tian Yang; Weiping Zhou; Mengchao Wu; Timothy M Pawlik; Wan Yee Lau; Feng Shen
Journal:  JAMA Surg       Date:  2018-10-17       Impact factor: 14.766

Review 8.  Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function.

Authors:  Taro Takami; Takahiro Yamasaki; Issei Saeki; Toshihiko Matsumoto; Yutaka Suehiro; Isao Sakaida
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

9.  Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy.

Authors:  Wen-Feng Gong; Jian-Hong Zhong; Bang-DE Xiang; LE-Qun Li
Journal:  Mol Clin Oncol       Date:  2016-04-22

10.  Distinguished prognosis after hepatectomy of HBV-related hepatocellular carcinoma with or without cirrhosis: a long-term follow-up analysis.

Authors:  Sheng-Li Yang; Li-Ping Liu; Yun-Fan Sun; Xing-Rong Yang; Jia Fan; Jian-Wei Ren; George G Chen; Paul B S Lai
Journal:  J Gastroenterol       Date:  2015-11-25       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.